Related Experiment Video
Updated: Feb 20, 2026
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
The PAH-AM-PEG-ApoE@siRNA Nanocarrier Delivery System for Polo-like Kinase 1 Inhibition Suppresses Glioma Progression
Feng Su1,2,3, Shengnan Lu3, Junli Zhang2
1Department of Pharmaceutics, China Pharmaceutical University, Nanjing, 211198, China.
Abstract:
The poor efficacy of chemotherapy for glioma is mainly due to the difficulty of drug penetration through the blood-brain barrier (BBB), as well as the difficulty of drug concentration in the tumor tissue to reach the effective therapeutic level. The emerging tumor-targeted delivery technology can facilitate the precise enrichment of drugs in the tumor site. Apolipoprotein E (ApoE(159-167)2) binds to low-density lipoprotein receptor-related protein 1 (LRP-1) on the blood-brain barrier and helps it to specifically cross the BBB. Based on this, in this study, poly (ethylene glycol) (PEG) dimerized with ApoE(159-167)2 was used for the modification of PAH-AM, and amphiphilic PAH-AM-PEG-ApoE nanocarriers were successfully prepared. Among them, the PEG modification could effectively prolong the retention time of the nanoparticles in vivo and reduce the toxic side effects, while the ApoE(159-167)2 polypeptide could specifically penetrate the blood-brain barrier for intracerebral targeted delivery by binding to LRP-1. The nanocarrier further binds to small interfering RNA (siRNA) targeting PLK1, a key cell cycle factor, by electrostatic interaction to construct the nano-delivery system PAPA@siPLK1. In vitro experiments showed that the nanoparticles significantly inhibited the proliferation of U87MG glioma cells, induced apoptosis, and specifically silenced the mRNA and protein expression of PLK1. The results of in vivo animal experiments showed that PAPA@siPLK1 could effectively inhibit tumor growth and had potential brain permeability; The PAPA@siPLK1 nanocarrier delivery system developed in this study achieves PLK1 gene silencing through efficient siRNA delivery, providing an important basis for novel therapeutic strategies for glioma.
Insights
This study developed novel nanocarriers for glioma treatment. These carriers effectively deliver siRNA to brain tumors, inhibiting growth and silencing PLK1, offering a promising new therapy.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Glioma chemotherapy faces challenges due to the blood-brain barrier (BBB) limiting drug penetration and concentration.
- Tumor-targeted delivery systems are crucial for enhancing drug efficacy at the tumor site.
- Apolipoprotein E (ApoE) facilitates crossing the BBB by binding to low-density lipoprotein receptor-related protein 1 (LRP-1).
Purpose of the Study:
- To develop novel amphiphilic nanocarriers for targeted glioma treatment.
- To utilize ApoE for specific blood-brain barrier (BBB) penetration and intracerebral delivery.
- To construct a nanodelivery system for PLK1 gene silencing in glioma cells.
Main Methods:
- Modification of PAH-AM with poly (ethylene glycol) (PEG) and ApoE(159-167)2 to create PAH-AM-PEG-ApoE nanocarriers.
- Loading of small interfering RNA (siRNA) targeting PLK1 onto the nanocarriers via electrostatic interaction, forming PAPA@siPLK1.
- In vitro evaluation of U87MG glioma cell proliferation, apoptosis, and PLK1 gene silencing.
- In vivo assessment of tumor growth inhibition and brain permeability in animal models.
Main Results:
- Successfully prepared amphiphilic PAH-AM-PEG-ApoE nanocarriers with enhanced BBB penetration via ApoE.
- PAPA@siPLK1 effectively inhibited U87MG glioma cell proliferation and induced apoptosis in vitro.
- Demonstrated significant PLK1 mRNA and protein silencing in glioma cells.
- In vivo studies showed effective inhibition of tumor growth and potential for brain permeability.
Conclusions:
- The PAPA@siPLK1 nanocarrier system achieves efficient siRNA delivery for PLK1 gene silencing in glioma.
- This novel nanodelivery system shows significant potential for developing new therapeutic strategies against glioma.
- The ApoE-modified nanocarriers offer a promising approach for overcoming BBB limitations in brain tumor treatment.
